General Information of Drug (ID: DM8L1GJ)

Drug Name
SNA-125 Drug Info
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Phase 1 [1]
Pruritus EC90 Phase 1 [1]
Psoriasis vulgaris EA90 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM8L1GJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Janus kinase 3 (JAK-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [2]
Ritlecitinib DMYKNME Alopecia areata ED70.2 Approved [1]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [3]
VX-509 DM2U3MX Rheumatoid arthritis FA20 Phase 2/3 [4]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [1]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [5]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [6]
TD-8236 DMTOMJN Asthma CA23 Phase 2 [7]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [8]
GDC-0214 DMCNSII Asthma CA23 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
4 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
5 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
6 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
8 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
9 Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789.